Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Inhaled epoprostenol for acute respiratory distress syndrome

Schroeder, Nicole M., PharmD, BCPS, BCCCP; Castiello, Danielle R., BSN, RN, CCRN; Siemianowski, Laura A., PharmD, BCPS, BCCCP

doi: 10.1097/01.CCN.0000534919.47806.75

Abstract: Acute respiratory distress syndrome (ARDS) is associated with high rates of mortality. Inhaled nitric oxide and inhaled epoprostenol (iEPO) are inhaled pulmonary vasodilators used for adjunctive management in patients with severe ARDS. This article describes the safe and effective use of iEPO in patients with refractory hypoxemia.

This article describes the safe and effective use of inhaled epoprostenol in patients with acute respiratory distress syndrome (ARDS) by examining the current literature published on this topic.

Nicole M. Schroeder is a medical science liaison-idiopathic pulmonary fibrosis at Boehringer Ingelheim.

Danielle R. Castiello is a clinical educator on the ICU and Coronary Care Unit at Cooper University Hospital, Camden, N.J.

Laura A. Siemianowski is a clinical pharmacy specialist at Hospital of the University of Pennsylvania, Philadelphia, Pa.

The authors have disclosed no financial relationships related to this article.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved